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Evidence synthesis based on the quantitative analysis (indirect treatment com-
parisons ITC) of data from randomized controlled trials (RCTs) is the gold standard 
in healthcare decision making. However, when ITC of RCTs may not be practical or 
possible, comparative observational data may provide a valuable alternative despite 
potential challenges with internal validity. The present project aims to develop a 
conceptual framework from which valid quantitative assessment of real-world evi-
dence (RWE) can provide necessary insights into treatment effects outside the RCT 
settings. Considerations of quantitative evidence synthesis in RWE were identified 
using published best-practice guidelines for quantitative analysis of RCT data and 
applied to two test cases, atrial fibrillation (AF) treated with novel oral anticoagulant 
(NOAC) and type II diabetes treated with antihyperglycemic agents. Data sources of 
RWE, sample selection, outcome definitions, and statistical method variation were 
assessed. Significant variations across all key factors were observed in studies for 
both indications. In the case of NOAC treated AF, homogeneity of the data source 
and geographic location did not guarantee appropriate quantitative comparison. 
Several factors unique to assessing observational database study comparability for 
meta-analyses were identified including a need for a greater focus on selection bias 
inherent to the type and location of the database and increased sensitivity of esti-
mates to the index dates particularly in relation to local and international product 
launches, as well various outcome definition and reporting complexities. Valid ITC 
could be performed using RWE from comparative observational studies. Careful 
selection of studies is required to mitigate factors that would otherwise compro-
mise results through uncontrolled bias. Researchers need to go beyond the obvious 
individual study reporting biases and fully assess the complexities of comparative 
data sources to be able to appropriately select studies for ITC.
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The participation of society in HTA is crucial and needs to be implemented. In the 
last years, it has been analyzing, discussing, and questioning how to actually intro-
duce the public’s participation into HTA processes within the Brazilian Public Health 
System (SUS) perspective. In 2011, Law 12,401 was enacted, making the participation 
of civil society official within the process of incorporating technologies in the health 
system through: the participation of a representative of the National Health Council 
(CNS) on the National Committee for Health Technology Incorporation (CONITEC); 
the execution of a Public Consultation (PC) for each theme evaluated by CONITEC; 
and through a Public Hearing prior to final decision-making, in case the relevance of 
the matter should justify such a hearing. The aim of this abstract is to describe the 
activities which are being developed after a study published in 2013 which identified 
proposals for improving the mechanisms of society’s involvement in the processes 
of the assessment and incorporation of technologies into the SUS. Many of these 
proposals, among others, are being implemented by the Executive Secretariat of 
the CONITEC. Some of those proposals were to improve its disclosure and to attain 
a better use of social media. We started to disseminate information regarding PC 
through social network, website and mailing lists to the interested audiences, in 
addition to producing reports in an appropriate language for patients, which was 
another proposal made previously by the cited study. Furthermore, a new PC form 
was especially created in order to report the society’s perspective (patients, caregiv-
ers and health professionals’ experiences) and a Guide to HTA for Patients is also 
being produced. Public Consultations as a tool for the inclusion of society in HTA is 
legitimate and innovative; improve this will increase Patient and Public Involvement 
in the Brazilian HTA process.
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Meta-analyses in the classical sense, comparing two treatments across clinical tri-
als, are used for information synthesis during all phases of clinical research and 
development and especially in the context of reimbursement and assessment of 
relative effectiveness. In this meta-analytic framework we examined consistency 
of the relative treatment effect between groups of trials by application of a test for 
subgroup heterogeneity using aggregate trial data. A wide variety of software for 
performing meta-analyses and testing subgroup heterogeneity can be used, rang-
ing from ready-to-use systems like the Cochrane Collaboration’s RevMan software 
to packages requiring statistical expert knowledge. We applied this software and 
illustrate examination of heterogeneity in groups of trials by several examples. 
The first example investigates heterogeneity between groups of trials comparing 
different long-acting β 2-agonists (LABAs) versus Placebo with regard to exacerba-
tions in Chronic Obstructive Pulmonary Disease (COPD). Absence of heterogeneity 
was demonstrated and, hence, it turned out that the beneficial effect of Tiotropium 
in preventing COPD exacerbations, as e.g. directly demonstrated versus the LABA 
Salmeterol in the POET-COPD©trial, can be extended versus various LABAs. The 
second example examines heterogeneity in quality of life (QoL) as measured by the 
Saint George’s Respiratory Questionnaire (SGRQ) across Placebo-controlled COPD 
trial groups where Tiotropium was administered either open-label or blinded. It 
was shown that the magnitude of response with this QoL measure is inconsistent 
between open-label and blinded administration of Tiotropium with a higher benefit 
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BAckground: Treatments associated with excellent outcomes in a research set-
ting in randomised controlled trials (RCTs) may not be beneficial in the real-world 
settings which has a different spectrum of patients in different clinical situations. 
Therefore, healthcare providers are looking for evidence in the real-world setting in 
addition to RCTs. In this background, health insurance claims data are a source of 
invaluable real-world data. Claims data are increasingly being used for pharmaco-
economic and outcomes researchin regions like North America, Europe, Australia, 
and New Zealand. The major advantages of claims data over RCT data include: (a) 
health outcomes can be evaluated in real-world settings; (b) analysis results can 
be generalised to a broader population; (c) relatively inexpensivethan RCTs; (d) 
provide wide range of information about various conditions and procedures from 
a large number of patients, belonging to varied demographics; (e) data availability 
over extended periods of time allow retrospective cohort studies; (f) unaffected by 
recall bias; (g) large sample size will make the statistical methods more consistent. 
However, there are some limitations as well, such as incomplete diagnostic and 
provider identification data, and the fact that the population characteristics are 
largely influenced by the insurance plan, plan benefit design, and the variables 
of the database. Claims data in India are insufficiently used for health outcomes 
research. An important reason for this is that the penetration of health insurance is 
not up to the mark in India. It is expected that health insurance will become more 
popular in India, since (a) Indian health care expenditure is predominantly out-of-
pocket, and (b) the healthcare costs are escalating day-by-day. RECOMMENDATIONS: 
With the increased penetration of health insurance in India, appropriate analysis 
of the resulting claims data can provide invaluable insights into demographics, 
disease trends, efficacy and effectiveness, and real-world information, from the 
Indian perspective.
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Regulatory agencies are providing market authorization of pharmaceutical prod-
uct solely on the basis of efficacy, compliance and side effects derived from ran-
domised clinical trials (RCTs) which frequently fail to reflect real time use. It is 
important for the pharmaceutical companies and regulatory agencies to ensure 
that drug is performing well in the real world as it does in the closely monitored 
world of clinical trials. The payers like Medicare and Medicaid in the United States 
are also emphasizing on the drug benefits in real clinical practice. Also, the recent 
amendments in European Pharmacovigilance legislation emphasize continuous 
risk benefit assessment/risk management of pharmaceutical product following its 
launch in European market. Thereby, sources of good quality RWE will be essen-
tial for companies to meet regulatory authority expectations. The key activities 
within the area of Risk Management include compilation of Risk Management 
Plans (RMPs) and aggregate reports such as the Periodic Safety Update Report 
(PSUR), Periodic Benefit Risk Evaluation Report (PBRER), and the Development 
Safety Update Report (DSUR). These pharmacovigilance competencies can prove 
to be very useful in identifying drug’s risk-benefit profile which includes potential 
safety concerns, risk factors, effectiveness measures, safety signals, and target 
population. By leveraging database and observational studies, signal detection 
algorithms, surveys and extensive pharmacovigilance competencies, following 
research objectives can be achieved with Real World Safety evidence: Define drug 
exposure; Assess the epidemiology of indication/target population; Identify poten-
tial safety concerns and characterize known risk factors; Determine prescrib-
ing conditions/patient characteristics for drugs; Determine the effectiveness of 
measures to minimize risk; Identify and evaluate safety signals in a systemized 
way; The above mentioned concepts can serve as a precursor for planning of RWE; 
prospective and retrospective studies which can lead to potential cost saving and 
efficient analysis of the safety apprehensions.
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Current practice in Life Cycle Assessment (LCA) has, until now, focused predomi-
nantly on charting the environmental footprint of products and systems in vari-
ous industries. LCA studies typically report the environmental damage on three 
Areas of Protection: Natural Resources, Ecosystem Quality and Human Health. 
The damage results from the cause-effect chain of the use of natural resources 
and the release of emissions during the life cycle of any product. The third Area 
of Protection Human health is based on e.g. particulate matter emissions causing 
respiratory diseases and health effects related to global warming such as a higher 
incidence of food and waterborne diseases or natural disasters. These effects are 
gathered under a common unit: the Disability Adjusted Life Year (DALY), which 
accounts for both the morbidity and mortality of diseases. In the pharmaceutical 
sector, several LCA studies have evaluated different parts of the supply chain. Drug 
production, patient transport and hospital heating all contribute to the global 
environmental damage, including Human Health, of a full medical treatment. 
However, medical interventions are predominantly evaluated on their treatment 
benefits and risks in terms of how a patient feels, functions and survives. In 
addition, their costs and benefits are also weighted against each other in order 
to define the cost-effectiveness of a medical treatment. We propose the addition 
of the environmental health burden to the current evaluation methodologies of 
a medical treatment. This would allow for a more holistic appraisal, taking into 
account the effects of health care indirect resource use and emissions. The exist-
ing state of the art methodology for the quantification of environmental Human 
Health damage is discussed.
